Anglo Asian Mining

What it does: Anglo Asian Mining is a gold and copper producer that’s listed on the Alternative Investment Market (AIM).

By Royston Wild. Thanks to its suite of gold projects, Anglo Asian Mining’s(LSE:AAZ) share price is rising rapidly as bullion’s multi-year bull run continues.

The small cap — which owns the Gadir and Gedabek gold, silver and copper mines in Azerbaijan — has risen 103% in value over the last year.

With macroeconomic and geopolitical uncertainty growing, and fears of resurgent inflation back on the boil, I think gold prices could have much further to go after hitting multiple new record highs in 2025.

However, Anglo Asian Mining’s foothold in the gold industry isn’t the only reason why I think it could be a hot growth stock to consider. I’m also encouraged by its plans to supercharge copper production to capitalise on the fast-growing green economy.

It plans to open several new red metal mines over the next few years, which it hopes will take annual copper production to 36,000 tonnes by 2028 from 15,000-15,500 today.

Any setbacks at the mine development stages could hit Anglo Asian Mining’s share price hard. But I think this is reflected in the company’s cheapness (it trades on a price-to-earnings (P/E) ratio of 6.1 times).

Royston Wild does not own shares in Anglo Asian Mining.

Animalcare Group

What it does: Animalcare Group develops and markets veterinary pharmaceuticals and identification products.

By Mark Hartley. The AIM-listed veterinary pharmaceutical and identification group Animalcare (LSE: ANCR) looks like an intriguing small-cap investment to me. Earnings have exploded recently, leading to a six-fold increase in its net margin. This was driven by strategic divestments, including the sale of Identicare and a minority stake in STEM.

However, debt has also skyrocketed to £23.16m, almost double that of its available cash. For now, it’s sufficiently covered by equity — but could be at risk if profits slip. Being a small-cap, it may also experience higher volatility and lower liquidity compared to larger firms.

With the price slow to catch up with earnings, it has a forward price-to-earnings (P/E) ratio of only 16, which is well below the sector average of 40. This suggests it has more room for growth. It also boasts an attractive return on equity (ROE) of 36.62% — a reassuring sign of efficient management and profitability. 

Mark Hartley doesn’t own shares in Animalcare Group.

Central Asia Metals

What it does: Central Asia Metals is a base metals producer with copper operations in Kazakhstan and a zinc and lead mine in North Macedonia.

By Paul Summers. Small-cap stocks usually require even more due diligence than your typical FTSE juggernaut, especially when their share prices have been on a downward trajectory. Central Asia Metals (LSE: CAML) is a great example.

Sure, ongoing geopolitical concerns combined with lower demand for one of the metals it digs up doesn’t exactly paint a pretty picture. And the miner obviously has no control over either. 

But these feel like short-term headwinds. Demand for copper is expected to shoot up over the next decade as the world transitions to green energy at an increasing pace. This could eventually make the current valuation of seven times forecast FY25 earnings look like a steal.

In the meantime, the stock yields a monster 11.5% as I type. I’d prefer this to be covered to a greater extent by profit but at least the firm’s balance sheet looks solid for now. 

Paul Summers has no position in Central Asia Metals

International Personal Finance

What it does: This financial services company provides home and digital credit to over 1.7m customers in nine global markets.

By Charlie Carman. Many individuals struggle to access loans from mainstream banks. That’s where a firm like International Personal Finance (LSE:IPF) steps in.

The growth opportunity in lending to underserved credit customers is huge. The company eventually aims to claim 2.5m customers, representing a small fraction of the addressable market of more than 70m people across its target geographies.

Business is humming along nicely. In the first quarter, customer lending grew by 12%, driven by strong performances in Poland, Romania, Mexico, and Australia. Bolstering the investment case, a £15m share buyback programme is due to commence imminently, and shareholders also benefit from a mighty 7.4% dividend yield.

All lending businesses face risks. However, International Personal Finance has a riskier customer base than most, given its inability to access conventional credit. That shouldn’t be ignored, but a cheap valuation and plenty of room for expansion make the risks tolerable in my view.

Charlie Carman does not own shares in International Personal Finance.

The post 4 small-cap stocks Fools think have explosive growth potential appeared first on The Motley Fool UK.

A pet favourite

Trading at Pets At Home (LSE:PETS) has remained rock solid in spite of the ongoing cost-of-living crisis. Yet shares in the FTSE 250 retailer have plummeted on fears over future profits at its veterinary services unit.

This month the Competition and Markets Authority said it would investigate whether vets are giving pet owners good value for money. The regulator plans to look at issues like pricing transparency and information on whether surgeries are part of a broader group.

Pets At Home’s veterinary division is the fastest-growing part of the business. So it’s perhaps no surprise that investors have been spooked (like-for-like sales here jumped 16.6% during the 20 weeks to 20 July).

However, the company — which last year made 37% of underlying pre-tax profits from its vetcare arm — is far less exposed than specialist vetcare providers like CVS Group. In fact there’s plenty of reason to expect earnings here to continue growing strongly over the next several years.

Riding the wave

Pet ownership in the UK is on a long-term uptrend, meaning that demand for food, toys and other animal-related products should keep rising. Pets At Home is increasing its share of this expanding market too (its total take has improved 600 basis points to 24% in the last five years).

This is thanks in part to the growing popularity of its VIP loyalty scheme, which rose another 4% in the aforementioned 20-week period. Huge investment in e-commerce is also paying off handsomely, and new versions of its app and website are due later this year to support future growth.

Today Pets At Home shares trade on a forward price-to-earnings (P/E) ratio of 16.3 times. They also carry a meaty 3.8% corresponding dividend yield. I think this represents solid value given the retailer’s excellent momentum.

More animal magic

Pharmaceuticals manufacturer Animalcare (LSE:ANCR) is another UK share I’m looking at buying next month.

As the name implies, it specialises in manufacturing drugs for non-humans. This gives it a chance to capitalise on soaring pet adoption rates as well.

I also like Animalcare because it trades at a big discount to FTSE 100 industry peer Dechra Pharmaceuticals. It currently boasts a forward P/E ratio of 12.9 times, far below its bigger rival’s corresponding multiple of 29.7 times.

Revenues and operating profits at the firm dropped 4.1% and 2.8% respectively in the 12 months to June 2022. However, this decline simply reflects a return to pre-pandemic growth rates in the veterinary sector. It’s my opinion that the long-term sales outlook remains robust.

Animalcare is putting its strong balance sheet to work to capitalise on this opportunity too. It’s spending to improve its sales and marketing operations and is hunting for fresh earnings-boosting acquisitions.

Drugs development can be high-risk and Animalcare is no exception. But I still believe the AIM share remains a good UK stock to buy this October.

The post 2 top value UK shares I’d buy in October! appeared first on The Motley Fool UK.

Animalcare Group

The pharmaceuticals market for animals is growing rapidly. The amount people shell out to keep their companion creatures healthy is on a long-term uptrend. Spending here has also proved to be remarkably resistant during this tough economic period.

At the same time, demand for drugs for livestock is increasing strongly. And as an expanding global population boosts demand for food animals, it’s on course for further stratospheric growth.

Analysts at Precedence Research expect the global veterinary medicine market to be worth $93.7bn by 2032. That’s more than double what the sector was valued at last year.

This all explains why City analysts expect Animalcare Group’s (LSE:ANCR) bottom line to keep steadily expanding. Annual earnings are tipped to increase 5% in 2023 and 12% next year.

Following the 2017 acquisition of Ecuphar the business has a presence in seven European markets. It also has a growing network of distribution partners to sell products across the continent. And the firm has a €10m borrowing facility it can use specifically for acquisitions to boost profit growth.

Rising scrutiny from lawmakers in some markets poses a threat to Animalcare’s growth potential. Indeed, sales fell 3.3% in 2022 due in part to EU laws implemented in Spain to limit antibiotic use.

Calls are also rising from investors for companies to use fewer antibiotic drugs with livestock. Legal & General, for instance, says it will push McDonald’s to write a report on the public health impact of these drugs at the burger firm’s AGM this week.

That said, I still believe investing in Animalcare could be highly lucrative as demand for other drugs balloons.  

dotDigital Group

Tech businesses with expertise in artificial intelligence (AI) could also record explosive profits growth over the next decade. One such UK share on my radar today is dotDigital Group (LSE:DOTD).

Fresh spending from Qatar’s sovereign wealth fund underlines the huge investment potential of AI stocks. It was announced on 23 May that the Middle Eastern fund has ploughed a whopping $250m into London-based Builder.ai, which uses AI to build software.

dotDigital could also prove a winner in the years ahead. Its technologies allow e-tailers to automate their marketing operations, provide a tailored experience for online consumers, and stay connected with their customers though email campaigns.

Okay, analysts expect the company to experience a rare earnings fall (of 4%) in the financial year to June. But the business is expected to bounce back immediately. Bottom-line rises of 5% and 9% are currently anticipated for fiscal 2024 and 2025, respectively.

Tough economic conditions could put earnings forecasts for this year and next in jeopardy. Still, as a long-term investor I’d buy dotDigital shares for the robust profits growth I’m expecting further out.

The post 2 UK growth shares I’d buy for my Stocks & Shares ISA in June! appeared first on The Motley Fool UK.

Totally

An ongoing government push to divert patients away from hospitals bodes well for Totally (LSE:TLY). The business operates the NHS 111 telephone consultation service. It also runs urgent care centres and out-of-hours GP surgeries, services that are easing the strain on packed casualty wards.

Record hospital waiting lists are also driving revenues at the small-cap. This is because hospitals are subcontracting out medical work to slash patient treatment waiting times.

CIty analysts think Totally’s earnings will soar 430%-plus in the financial year to March. A 36% increase is expected in the following year too.

Potential changes to NHS policy could disrupt earnings growth at the firm. But any amendments could still be offset by booming demand for healthcare services as Britain’s population rapidly ages.

H&T Group

I think H&T Group could be a perfect stock to own as the UK faces a prolonged recession. City analysts think earnings at the pawnbroker will rise 60% in 2023 and 20% next year.

I believe the AIM share might be a great buy for the longer term too. This is not just because Britain faces low economic growth for much of the decade, due to Brexit and a Covid-19 hangover. The company plans to rapidly expand its store estate following a £17m share placing last September.

Changes to financial regulations could hamper profits growth. But as things stand, I’d still buy H&T shares with spare cash to invest.

Animalcare Group

Medicines developer Animalcare Group (LSE:ANCR) creates products for pets and livestock. And it is expected to grow annual earnings by double-digit percentages through to 2024 at least.

People are spending increasing sums of money on their companion animals. At the same time, rising meat consumption is driving drug sales for livestock. This is why analysts at Grand View Research think the global veterinary medicine market will grow to be worth a whopping $83.39bn by 2030, up from $47.91bn today.

Animalcare sells its products in Europe and is growing its distribution partners in other global markets too. It could therefore be a great way to capitalise on this growing market. I’d buy the business even though drugs development problems can take a big bite from profits.

Midwich Group

Tough economic conditions pose a near-term threat to audiovisual equipment supplier Midwich Group. However, City analysts still expect the business to grow earnings strongly through to next year.

Bottom line rises of 11% and 5% are forecast for 2023 and 2024 respectively. The company sells to trade customers across Europe, North America and Asia. And these bright growth forecasts reflect the predicted impact of the firm’s ambitious global expansion programme.

Midwich raised its revolving credit facility in December too, in order to fund future acquisitions. This rose to £175m from £80m and could help lay the foundations for excellent long-term growth.

The post AIM shares: 4 growth stocks I’d buy to hold for 10 years appeared first on The Motley Fool UK.

Here are three cheap UK shares I’d consider buying if they fall far in price. Each currently changes hands for less than £3.50.

A defensive hero

We have to spend to fill our bellies even when broader economic conditions worsen. This is why I think Devro (LSE: DVO) could be a top stock to buy if it falls amid a broader stock market crash. This cheap UK share manufactures sausage skins that it sells across developed and emerging markets.

I’ve long liked Devro because of the massive investment it has made in fast-growing developing territories, China, in particular. Meat demand in these geographies is tipped to keep rising strongly as personal income levels rise. Indeed, Devro’s latest financials said that it enjoyed strong growth in Latin America, the Middle East, and Africa during the four months to October. I’d buy the business despite the threat posed to its operations by the growing popularity of vegetarian and vegan diets.

Riding the petcare boom

People in Europe are spending more and more money to keep their companion animals happy and healthy. This is what makes Animalcare Group (LSE: ANCR) such an attractive stock in my book. Analysts at the Business Research Company think the global animal medicine market will be worth $85.1bn by 2030. That compares with the $42.5bn it was estimated at in 2019.

I am aware, however, that Animalcare (like Devro) could be hit by the rise of meat-free diets. This is because the business supplies medicines for livestock as well as for pets in Europe. Indeed, a report by Smart Protein over the summer showed that 46% of Europeans had reduced their meat consumption on a 12-month basis. Still, I think the bright outlook for the petcare market offsets this threat.

A consumer goods colossus

I bought Unilever shares because I considered it to be a relatively secure place to park my money. Products like Dove soap, Magnum ice cream, and Domestic bleach give it a market-leading position in ultra-defensive food and household and personal goods markets. I am also considering snapping up PZ Cussons (LSE: PZC) for my portfolio because it shares the same qualities. Brands like Imperial Leather soaps have been excellent sales generators for the business for decades now.

PZ Cussons has a great track record of innovating its powerhouse labels to keep consumers interested. And it has supercharged marketing investment in the likes of Imperial Leather, too. I also reckon the business will benefit from changing consumer attitudes towards hygiene following the Covid-19 outbreak. Despite the threat of rising raw material costs, I think PZ Cussons (like Unilever) could thrive even if the economic recovery runs out of steam.

The post Cheap UK shares to buy if the stock market crashes again! appeared first on The Motley Fool UK.

Buying a pharma stock like this is risky business as drugs production is naturally complex and failures at the lab bench can cost a fortune in lost revenues and additional development costs. But that’s not to say that investment here is a bad idea. Analysts at Grand View Research think the animal medicines market will grow 80% between now and 2028 when it will be worth $88.7bn.

An advantage that Animalcare has over CVS is its huge exposure to the livestock industry. It’s a market that’s set for massive growth as global meat consumption is set to rise considerably. Revenues at Animalcare soared 13.3% in the six months to June. And the business has committed to increasing investment in its product pipeline over the next couple of years to keep turnover ripping higher.

Market leader

I’m also considering buying penny stock HSS Hire Group (LSE: HSS) right now. It’s a market leader in the tool and equipment rental industry, with around 250 stores running the length and breadth of the country. This gives it the scope to capitalise on the UK’s home improvement boom.

Spending on DIY projects rocketed during the Covid-19 lockdowns. And the amount Britons spend on home remodelling looks set to remain strong too, underpinned by a strong domestic housing market and the huge savings people accrued during the pandemic.

I think HSS has the clout to capitalise on these favourable conditions to the max. And I also like the huge investment the firm has made to improve its digital operations, enabling it to exploit the e-commerce boom more fully. I’d buy this cheap UK share despite the fact it operates in a highly-competitive marketplace.

I’d buy this cheap UK share too!

I also think Halfords Group (LSE: HFD) is another great low-cost stock for me. That’s even though the retailer’s profits can fall sharply when economic conditions worsen and consumer spending comes under the cosh.

As you might know, Halfords sells huge volumes of car accessories and provides auto servicing and maintenance to its customers too. It is also the biggest seller of bicycles and cycle parts in the country.

This latter role is what makes it such an attractive stock, in my opinion. Bike sales are going through the roof as people seek a more environmentally-friendly ways to get around. The rising importance of personal fitness with consumers is also lighting up sales.

Demand for bikes should also benefit from massive government spending to upgrade cycling infrastructure in the UK. Halfords, with its position as a one-stop-shop for everything bicycle related, and home to extremely-popular brands such as Boardman and Pendleton stands to gain enormously in this environment.

The post £1k to invest? Cheap UK shares below £3 to buy right now! appeared first on The Motley Fool UK.

I first bought CVS Group because the amount people spend to take care of their animals has soared in recent years. The onset of Covid-19, and the subsequent impact on pet adoption rates, has given UK shares like this an extra shot in the arm too. Latest financials from Animalcare showed that the boom in companion animal ownership lifted revenues 13% higher between January and June as demand for its drugs soared.

Buying pharmaceutical shares can be risky business. Drugs can fail at the testing stage and regulators can refuse to sign a product off for sale. This can create mammoth additional costs and leave a gaping hole in the revenues column.

What’s more, Animalcare’s high valuation leaves the stock in danger of a sharp share price reversal if it does indeed encounter such problems. City analysts think earnings at the UK healthcare share will rise 4% in 2021. Consequently it trades on a hefty forward price-to-earnings (P/E) ratio of around 33 times.

Why I’d still buy this UK share

That said, I’d still consider investing in Animalcare today. This is not just because the rate at which the animal drugs market is set to explode. Statista says the animal medicine market will be worth $68bn by 2023, up more than 60% from 2019 levels.

It’s also because Animalcare has a packed pipeline of products such as canine osteoarthritis pain reliever Daxocox which is set for launch in late 2020. As well, I think the pharma play’s decision to concentrate on higher-margin novel products over generic drugs could pay off handsomely.

The A Team

Team17 Group (LSE: TM17) is another top UK share that doesn’t come cheap. The number crunchers think earnings here will rise 5% in 2021, resulting in a forward P/E ratio of approximately 41 times.

However, I’d take advantage of a recent share price slump for the video games developer. Indeed, I’d buy it with one eye on results which are due to come out (on Tuesday, 14 September). I think this could remind the market of its brilliant investment potential as the video games market goes from strength to strength. Recent data shows the gaming industry is now worth more than the movie and music industries combined.

Team17’s broad selection of popular games helped revenues surge 34% in 2020 and 43% the year before that. Now the video games market is massively competitive and there’s no guarantee that a future title will prove a hit. But I like this UK share’s track record and think it could be one of the best stocks I could buy to ride the gaming revolution.

The post 2 of the best UK stocks to buy in September appeared first on The Motley Fool UK.

According to a Fortune Business Insight report, the worldwide vet drugs market will surge to $27.6bn by 2025. This would represent an almost-$10bn jump in a mere eight years. It also suggests a healthy compound annual growth rate of 5.6%. And it’s a market which Animalcare Group (LSE: ANCR) is well placed to capitalise on.

Moving back into growth?

This AIM-quoted business develops, supplies and markets various products and services to vets across the world. Trading here hasn’t been that strong of late, sure. Sales fell 1.5% in 2019, it said last week, because of supply-side issues and falling use of antibiotics for livestock.

However, the launch of new products recently should help it recover. Animalcare cut the ribbon on four new drugs last year alone, and hopes to receive regulatory sign off on another in 2020. It also plans to submit a pain-relieving treatment for approval this quarter.

City analysts expect Animalcare to bounce back into the black with a 2% earnings rise this year. And predictions of improving momentum lead to expectations of a 6% bottom-line increase in 2021.

Balance sheet betterment

The huge improvement Animalcare is making to its balance sheet bodes well for the future too. Underlying cash conversion rose to 92.3% in the first half of 2019, up from 80% the year before. And the business confirmed last month it expects to report a “significant improvement” in the rate when full-year results come out on 31 March.

Thanks to this exceptional cash conversion net debt is toppling too. This fell by around a third year-on-year in 2019 to £15.9m, Animalcare has said. This further bolsters the company’s financial firepower when it comes to investing in R&D to drive future growth.

Animal magic

Now Animalcare isn’t exactly cheap. Not on paper at least. At current prices it carries a forward P/E ratio of 16.2 times. Such a reading may put off many stock pickers given the supply-related issues it’s had of late too.

I consider this reading to be quite undemanding though, when you consider the company’s immense structural opportunities in the next decade and beyond. Besides, those supply problems it experienced with third-party manufacturers last year are a thing of the past.

In fact, the petcare specialist still trades at a considerable discount to some of its industry rivals on the back of these previous troubles. Fellow drugmaker Dechra Pharmaceuticals for instance trades on a forward P/E multiple of above 30 times. Those looking for solid growth prospects at great value need to give Animalcare some close attention today.

The post ISA investors! Could this megatrend help you get rich and retire early? appeared first on The Motley Fool UK.

As my colleague Edward Sheldon recently commented, the world is set to experience a boom in the number of so-called silver surfers in the coming decades, a surge in the number of citizens over the age of 60. With this comes rising healthcare demand, naturally, and this is a phenomenon that GlaxoSmithKline, with its broad range of treatments, is in prime position to exploit.

This isn’t the only reason to pile in to GlaxoSmithKline today. Investors in the pharmaceuticals arena need to be prepared for long, frustrating and often extremely-expensive product launch delays in the event of poor testing data and/or the thumbs-down from regulators. The FTSE 100 firm has a great track record of getting its products to market relatively quickly, however, a critical quality in recent years as the business has suffered from crushing patent losses such as that of Advair.

Hospitals hero

Investors still concerned about the unpredictability surrounding drugs pipelines may be tempted to buy in to fellow Footsie share NMC Health (LSE: NMC) instead.

Like GlaxoSmithKline, the private healthcare provider is also in great shape to ride the boom of ageing citizens. It is, however, involved in offering a range of medical services from gynaecology and obstetrics though to drugs dispensing, although it is probably more famous for its hospital network which spans the United Arab Emirates.

In total NMC can actually boast a network of 185 facilities in 17 countries, a footprint that has been helped by rampant acquisition activity. It’s well placed to benefit from citizens’ booming wealth in the Emirates, but it is not content to rest on the exceptional emerging market revenues opportunities that it has. More specifically, it has stated its intention in recent times to get a slice of the fast-growing fertility clinic market and is looking to open a swathe of such clinics across Europe.

A pet pick

Looking at the business of healthcare though a different lens, Animalcare (LSE: ANCR) is a very-promising pharmaceuticals play focused on helping our sick four-legged friends. The business of providing medicines to both agricultural and companion animals is becoming increasingly large, and thanks to its exceptional product ranges things look exceptionally healthy for the AIM-quoted firm.

Animalcare’s operations have been given a huge boost following the acquisition of Ecuphar last year, a move that has boosted its geographical reach as well as its operational clout. The rationale of the move was underlined by news released this week that revenues from pet products jumped almost 70% year-on-year between January and June, to £23.6m.

And investors should be encouraged by the company’s vow to supercharge its position in the high-margin veterinary pharmaceuticals products arena. Its declining share price suggests that the market remains unconvinced right now, but I reckon the earnings outlook for the business remains extremely exciting.

The post FTSE 100 dividend stock GlaxoSmithKline isn’t the only healthcare star that could help you retire rich appeared first on The Motley Fool UK.

Unfortunately not all investors in the UK and abroad are as clued up as they could be, so we’ve been at pains more recently to identify a number of investment strategies that could help you stave off retirement poverty.

In a recent article I selected some of the best dividend shares from the FTSE 250 that should more than offset any shortfall caused by the State Pension. Given the positive response to these picks from our audience, I’m at it again today, looking at two great pharmaceutical stocks that could help you to retire on a fortune: Hutchison China MediTech (LSE:HCM) and Animalcare (LSE: ANCR).

Tech This Out

Hutchison isn’t turning a profit right now. It isn’t expected to turn a profit by the end of the decade at least. But share investors who are in it for the long haul should give the Asia-focused medicines giant close consideration on the back of its bulging product pipeline.

On the immediate horizon, the market waits with baited breath for news on the company’s oncology treatment fruquintinib for the remainder of the year. It is expecting approval and launch of the product in China for colorectal cancer in the months ahead, and is also seeking Phase III testing results for lung cancer application soon.

Things are likely to remain exciting in 2019 and beyond. Following positive Phase II data on its savolitinib cancer battler, Hutchison has begun exploring the possibility of accelerated approval from Chinese regulators to bring the treatment to market sooner. In addition, another major drug, tumour treatment sulfatinib, is due to begin Phase III studies in China next year.

Hutchison’s global expansion strategy also offers plenty of reason to expect earnings to detonate in the years ahead. During Q2, its Hutchison MediPharma (US) division started operating in New Jersey, a move designed to bolster its R&D and regulatory activities outside of Asia and also prepare the ground for new product launches.

Animal magic

The ballooning market for veterinary medicines also makes fellow AIM stock Animalcare a hot growth prospect.

Investor appetite soured in the spring after it warned that the impact of a changing sales mix on gross margins, allied with a recent rise in competitive pressures, would see earnings fall short of expectations in 2018. This subsequent re-rating now leaves Animalcare dealing on a forward P/E ratio of 12.6 times, and this represents a brilliant time for patient investors to jump in, I believe.

Revenues at the business rose 6.4% in the six months to June, it advised in August, and its bubbly pipeline promises more impressive top-line progress. It has several product launches slated for the remainder of 2018 and for the start of next year,  including Cortacare which received approval from the Committee for Medicinal Products for Veterinary European Medicines in June.

An added reason to investing in Animalcare is that the business, unlike the vast majority of pharma players, offers quite fatty dividend yields — for 2018 and 2019 these sit at 4.2% and 4.3% respectively. There’s still a lot to cheer over at the business, and especially at current prices. It’s a great buy in my book.

The post Don’t worry about the State Pension! These 2 pharma stocks could make you VERY wealthy appeared first on The Motley Fool UK.